FINWIRES · TerminalLIVE
FINWIRES

Cynata Therapeutics Gets Positive European Opinion for Acute Graft Versus Host Disease Trial

By

Cynata Therapeutics (ASX:CYP) received a positive opinion from the European Medicines Agency's Paediatric Committee for a plan to develop its CYP-001 product candidate for the treatment of acute graft versus host disease, according to a Wednesday filing with the Australian bourse.

The committee has agreed to the company's proposed pediatric investigation plan, which is a requirement to start a phase 3 clinical trial in the European Union.

CYP-001 is designed for intravenous use to modulate the immune system and improve response rates and survival outcomes in acute graft versus host disease, an often life-threatening complication of bone marrow transplantation and similar procedures, per the filing.

Cynata Therapeutics plans to launch a phase 3 clinical trial first in adults, and once the primary analysis of the adult trial is complete, it plans to start a pediatric clinical trial.

Related Articles

Asia

Pacific Edge Completes Over NZ$36 Million Equity Raise; Shares Tumble 5%

Pacific Edge (NZE:PEB, ASX:PEB) completed its NZ$36.1 million equity raising at NZ$0.17 per share, comprising a NZ$25.4 million placement and an oversubscribed retail offer that drew NZ$46 million in applications, with NZ$10.7 million accepted, according to a Wednesday Australia and New Zealand bourse filing.The company raised NZ$10.2 million through a share purchase plan and a further NZ$500,000 under placement capacity from the retail proceeds, per the filing.The company will issue 62.7 million new shares under the retail offer, expected to be allotted and to commence trading on the New Zealand Exchange on Thursday, ranking equally with existing ordinary shares, the filing added.The company's Kiwi shares tumbled 5% in recent Wednesday trade.

$ASX:PEB$NZE:PEB
Asia

Ardea Resources Says Finalization of Definitive Feasibility Study to Extend Beyond June

Ardea Resources (ASX:ARL) said completion of the definitive feasibility study final report for the Kalgoorlie project-Goongarrie Hub in Western Australia is expected to extend beyond June 30, according to a Wednesday filing with the Australian bourse.Value engineering opportunities identified during the quarter may need further input for the study before finalization, the filing said.The company initiated a scoping study to assess the potential recovery of scandium and other critical minerals, which is anticipated to be completed in September, per the filing.

$ASX:ARL
Asia

Opthea Poised to Resume Trading on Australian Securities Exchange After Decision to Advance Lung Disease Drug Candidate

Opthea (ASX:OPT) expects to resume trading on the Australian Securities Exchange on or around Wednesday following a decision to advance its OPT-302 drug candidate for the treatment of lymphangioleiomyomatosis, according to a same-day filing with the Australian bourse.Lymphangioleiomyomatosis is a chronic lung disease that mainly affects women, characterized by the destruction of lung tissue.Opthea believes its scientific assets, manufacturing capabilities, and intellectual property portfolio "provide a strong foundation" for a strategy focused on the disease, where a significant unmet medical need exists.The company has launched a staged development program over an expected 18-month period to evaluate OPT-302, it said.

$ASX:OPT